<i>STK11</i>/<i>KEAP1</i> co-mutations in <i>SMARCA4</i>-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacy.

ABSTRACT:

Background

The impact of STK11/KEAP1 co-mutations on the efficacy of immunotherapy in patients with SMARCA4-mutant advanced non-small cell lung cancer (NSCLC) remains incompletely understood. Our aim was to investigate the effects of STK11/KEAP1 co-mutations on the clinical prognosis of patients with SMARCA4-mutant advanced NSCLC receiving immunotherapy.

Methods

We obtained 2,098 patients with stage IIIB-IV NSCLC from the cBioPortal database. Patients harboring EGFR, ALK, ROS1 and RET mutations were excluded. The impacts of SMARCA4 and STK11/KEAP1 co-mutations on the efficacy of chemoimmunotherapy were analyzed, along with their associations with tumor mutational burden (TMB), programmed cell death ligand

SUBMITTER: Dong Z 

PROVIDER: S-EPMC12432681 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature